4//SEC Filing
MOEBIUS HANS 4
Accession 0001209191-24-001157
CIK 0001620463other
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 4:45 PM ET
Size
6.1 KB
Accession
0001209191-24-001157
Insider Transaction Report
Form 4
MOEBIUS HANS
Chief Medical Officer
Transactions
- Award
Common Stock
2024-01-04+10,000→ 91,482 total
Footnotes (2)
- [F1]On November 3, 2021, the reporting person was granted restricted stock units ("RSUs") representing 30,000 shares of Common Stock of the Issuer. The RSUs are scheduled to vest according to the following amended vesting schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest as of the date the Compensation Committee (the "Committee") determines that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial has been completed, and (3) one third (1/3rd) of the number of shares subject to the RSU award vest as of the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the "LIFT-AD Readout"), in each case subject to continued service with the Issuer through the applicable vesting date.
- [F2]On January 4, 2023, the Committee determined that enrollment of the Company's LIFT-AD Phase 2/3 clinical trial had been completed and 10,000 RSUs vested and settled on such date.
Documents
Issuer
Athira Pharma, Inc.
CIK 0001620463
Entity typeother
Related Parties
1- filerCIK 0001822494
Filing Metadata
- Form type
- 4
- Filed
- Jan 7, 7:00 PM ET
- Accepted
- Jan 8, 4:45 PM ET
- Size
- 6.1 KB